Kidney health may change how drug works in body

NCT ID NCT06589713

Completed Knowledge-focused Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how different levels of kidney function affect the way the drug enpatoran moves through the body. 34 adults with normal or impaired kidney function received a single dose of enpatoran. Researchers measured drug levels in the blood and monitored for side effects to understand if kidney problems change how the drug is processed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: enpatoran
What this could lead to: If successful, this study could help doctors determine the right dose of enpatoran for people with kidney problems, making the drug safer and more effective.
What could go wrong: This is an early-phase study with only 34 participants, focused on drug levels and safety, not on treating a disease. Results may not apply to all patients or lead to a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease impaired renal function disease kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL IMPAIRMENT

Contacts and locations

Locations

CRS Clinical Research Services Kiel GmbH

Kiel, Schleswig-Holstein, 24105, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.